Added mass energy recovery of octopus-inspired shape change

Dynamic shape change of the octopus mantle during fast jet escape manoeuvres results in added mass energy recovery to the energetic advantage of the octopus, giving escape thrust and speed additional to that due to jetting alone. We show through numerical simulations and experimental validation of overall wake behaviour, that the success of the energy recovery is highly dependent on shrinking speed and Reynolds number, with secondary dependence on shape considerations and shrinking amplitude. The added mass energy recovery ratio η[subscript ma], which measures momentum recovery in relation to the maximum momentum recovery possible in an ideal flow, increases with increasing the non-dimensional shrinking parameter σ[superscript ∗]=ȧ[subscript max]/U√(Re[subscript 0]), where ȧ[subscript max] is the maximum shrinking speed, U is the characteristic flow velocity and √(Re0) is the Reynolds number at the beginning of the shrinking motion. An estimated threshold σ[superscript ∗]≈10 determines whether or not enough energy is recovered to the body to produce net thrust. Since there is a region of high transition for 10100 added mass energy is recovered at diminishing returns, we propose a design criterion for shrinking bodies to be in the range of 50<σ[superscript ∗]<100, resulting in 61–82 % energy recovery

Shape of retracting foils that model morphing bodies controls shed energy and wake structure

The flow mechanisms of shape-changing moving bodies are investigated through the simple model of a foil that is rapidly retracted over a spanwise distance as it is towed at constant angle of attack. It is shown experimentally and through simulation that by altering the shape of the tip of the retracting foil, different shape-changing conditions may be reproduced, corresponding to: (i) a vanishing body, (ii) a deflating body and (iii) a melting body. A sharp-edge, ‘vanishing-like’ foil manifests strong energy release to the fluid; however, it is accompanied by an additional release of energy, resulting in the formation of a strong ring vortex at the sharp tip edges of the foil during the retracting motion. This additional energy release introduces complex and quickly evolving vortex structures. By contrast, a streamlined, ‘shrinking-like’ foil avoids generating the ring vortex, leaving a structurally simpler wake. The ‘shrinking’ foil also recovers a large part of the initial energy from the fluid, resulting in much weaker wake structures. Finally, a sharp edged but hollow, ‘melting-like’ foil provides an energetic wake while avoiding the generation of a vortex ring. As a result, a melting-like body forms a simple and highly energetic and stable wake, that entrains all of the original added mass fluid energy. The three conditions studied correspond to different modes of flow control employed by aquatic animals and birds, and encountered in disappearing bodies, such as rising bubbles undergoing phase change to fluid

Feasibility study to assess the impact of a lifestyle intervention (‘LivingWELL’) in people having an assessment of their family history of colorectal or breast cancer

Objectives To assess the feasibility of delivering and evaluating a weight management (WM) programme for overweight patients with a family history (FH) of breast cancer (BC) or colorectal cancer (CRC).  Study design A two-arm (intervention vs usual care) randomised controlled trial. Setting National Health Service (NHS) Tayside and NHS Grampian.  Participants People with a FH of BC or CRC aged≥18 years and body mass index of ≥25 kg/m2 referred to NHS genetic services.  Intervention Participants were randomised to a control (lifestyle booklet) or 12-week intervention arm where they were given one face-to-face counselling session, four telephone consultations and web-based support. A goal of 5% reduction in body weight was set, and a personalised diet and physical activity (PA) programme was provided. Behavioural change techniques (motivational interviewing, action and coping plans and implementation intentions) were used.  Primary outcome Feasibility measures: recruitment, programme implementation, fidelity measures, achieved measurements and retention, participant satisfaction assessed by questionnaire and qualitative interviews.  Secondary outcomes Measured changes in weight and PA and reported diet and psychosocial measures between baseline and 12-week follow-up. Results Of 480 patients approached, 196 (41%) expressed interest in the study, and of those, 78 (40%) patients were randomised. Implementation of the programme was challenging within the time allotted and fidelity to the intervention modest (62%). Qualitative findings indicated the programme was well received. Questionnaires and anthropometric data were completed by >98%. Accelerometer data were attained by 84% and 54% at baseline and follow-up, respectively. Retention at 12 weeks was 76%. Overall, 36% of the intervention group (vs 0% in control) achieved 5% weight loss. Favourable increases in PA and reduction in dietary fat were also reported.  Conclusions A lifestyle programme for people with a family history of cancer is feasible to conduct and acceptable to participants, and indicative results suggest favourable outcomes.  Trial registration number ISRCTN13123470; Pre-results

Cardiorespiratory fitness is associated with hard and light intensity physical activity but not time spent sedentary in 10–14 year old schoolchildren: the HAPPY study

Sedentary behaviour is a major risk factor for developing chronic diseases and is associated with low cardiorespiratory fitness in adults. It remains unclear how sedentary behaviour and different physical activity subcomponents are related to cardiorespiratory fitness in children. The purpose of this study was to assess how sedentary behaviour and different physical activity subcomponents are associated with 10–14 year-old schoolchildren's cardiorespiratory fitness

Girls Are Good At STEM: Opening Minds And Providing Evidence Reduce Boys\u27 Stereotyping Of Girls\u27 STEM Ability

Girls and women face persistent negative stereotyping within STEM (science, technology, engineering, mathematics). This field intervention was designed to improve boys\u27 perceptions of girls\u27 STEM ability. Boys (N = 667; mostly White and East Asian) aged 9-15 years in Canadian STEM summer camps (2017-2019) had an intervention or control conversation with trained camp staff. The intervention was a multi-stage persuasive appeal: a values affirmation, an illustration of girls\u27 ability in STEM, a personalized anecdote, and reflection. Control participants discussed general camp experiences. Boys who received the intervention (vs. control) had more positive perceptions of girls\u27 STEM ability, d = 0.23, an effect stronger among younger boys. These findings highlight the importance of engaging elementary-school-aged boys to make STEM climates more inclusive

Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages

Pancreatic ductal adenocarcinoma (PDA) is accompanied by reprogramming of the local microenvironment, but changes at distal sites are poorly understood. We implanted biomaterial scaffolds, which act as an artificial premetastatic niche, into immunocompetent tumor-bearing and control mice, and identified a unique tumor-specific gene expression signature that includes high expression of C1qa, C1qb, Trem2, and Chil3 Single-cell RNA sequencing mapped these genes to two distinct macrophage populations in the scaffolds, one marked by elevated C1qa, C1qb, and Trem2, the other with high Chil3, Ly6c2 and Plac8 In mice, expression of these genes in the corresponding populations was elevated in tumor-associated macrophages compared with macrophages in the normal pancreas. We then analyzed single-cell RNA sequencing from patient samples, and determined expression of C1QA, C1QB, and TREM2 is elevated in human macrophages in primary tumors and liver metastases. Single-cell sequencing analysis of patient blood revealed a substantial enrichment of the same gene signature in monocytes. Taken together, our study identifies two distinct tumor-associated macrophage and monocyte populations that reflects systemic immune changes in pancreatic ductal adenocarcinoma patients

Stellar masses of SDSS-III/BOSS galaxies at z ~ 0.5 and constraints to galaxy formation models

We calculate stellar masses for ∼400 000 massive luminous galaxies at redshift ∼0.2–0.7 using the first two years of data from the Baryon Oscillation Spectroscopic Survey (BOSS). Stellar masses are obtained by fitting model spectral energy distributions to u, g, r, i, z magnitudes, and simulations with mock galaxies are used to understand how well the templates recover the stellar mass. Accurate BOSS spectroscopic redshifts are used to constrain the fits. We find that the distribution of stellar masses in BOSS is narrow (Δlog M ∼ 0.5 dex) and peaks at about log M/M⊙ ∼ 11.3 (for a Kroupa initial stellar mass function), and that the mass sampling is uniform over the redshift range 0.2–0.6, in agreement with the intended BOSS target selection. The galaxy masses probed by BOSS extend over ∼1012 M⊙, providing unprecedented measurements of the high-mass end of the galaxy mass function. We find that the galaxy number density above ∼2.5 × 1011 M⊙ agrees with previous determinations. We perform a comparison with semi-analytic galaxy formation models tailored to the BOSS target selection and volume, in order to contain incompleteness. The abundance of massive galaxies in the models compare fairly well with the BOSS data, but the models lack galaxies at the massive end. Moreover, no evolution with redshift is detected from ∼0.6 to 0.4 in the data, whereas the abundance of massive galaxies in the models increases to redshift zero. Additionally, BOSS data display colour–magnitude (mass) relations similar to those found in the local Universe, where the most massive galaxies are the reddest. On the other hand, the model colours do not display a dependence on stellar mass, span a narrower range and are typically bluer than the observations. We argue that the lack of a colour–mass relation for massive galaxies in the models is mostly due to metallicity, which is too low in the models

The Baryon Oscillation Spectroscopic Survey of SDSS-III

The Baryon Oscillation Spectroscopic Survey (BOSS) is designed to measure the scale of baryon acoustic oscillations (BAO) in the clustering of matter over a larger volume than the combined efforts of all previous spectroscopic surveys of large scale structure. BOSS uses 1.5 million luminous galaxies as faint as i=19.9 over 10,000 square degrees to measure BAO to redshifts z<0.7. Observations of neutral hydrogen in the Lyman alpha forest in more than 150,000 quasar spectra (g<22) will constrain BAO over the redshift range 2.15<z<3.5. Early results from BOSS include the first detection of the large-scale three-dimensional clustering of the Lyman alpha forest and a strong detection from the Data Release 9 data set of the BAO in the clustering of massive galaxies at an effective redshift z = 0.57. We project that BOSS will yield measurements of the angular diameter distance D_A to an accuracy of 1.0% at redshifts z=0.3 and z=0.57 and measurements of H(z) to 1.8% and 1.7% at the same redshifts. Forecasts for Lyman alpha forest constraints predict a measurement of an overall dilation factor that scales the highly degenerate D_A(z) and H^{-1}(z) parameters to an accuracy of 1.9% at z~2.5 when the survey is complete. Here, we provide an overview of the selection of spectroscopic targets, planning of observations, and analysis of data and data quality of BOSS.Comment: 49 pages, 16 figures, accepted by A

Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries.

Human lipoxygenases (hLO) have been implicated in a variety of diseases and cancers and each hLO isozyme appears to have distinct roles in cellular biology. This fact emphasizes the need for discovering selective hLO inhibitors for both understanding the role of specific lipoxygenases in the cell and developing pharmaceutical therapeutics. To this end, we have modified a known lipoxygenase assay for high-throughput (HTP) screening of both the National Cancer Institute (NCI) and the UC Santa Cruz marine extract library (UCSC-MEL) in search of platelet-type 12-hLO (12-hLO) selective inhibitors. The HTP screen led to the characterization of five novel 12-hLO inhibitors from the NCI repository. One is the potent but non-selective michellamine B, a natural product, anti-viral agent. The other four compounds were selective inhibitors against 12-hLO, with three being synthetic compounds and one being alpha-mangostin, a natural product, caspase-3 pathway inhibitor. In addition, a selective inhibitor was isolated from the UCSC-MEL (neodysidenin), which has a unique chemical scaffold for a hLO inhibitor. Due to the unique structure of neodysidenin, steady-state inhibition kinetics were performed and its mode of inhibition against 12-hLO was determined to be competitive (K(i)=17microM) and selective over reticulocyte 15-hLO-1 (K(i) 15-hLO-1/12-hLO\u3e30)

The Scleroderma Patient-centered Intervention Network (SPIN) Cohort : protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context

Introduction: Psychosocial and rehabilitation interventions are increasingly used to attenuate disability and improve health-related quality of life (HRQL) in chronic diseases, but are typically not available for patients with rare diseases. Conducting rigorous, adequately powered trials of these interventions for patients with rare diseases is difficult. The Scleroderma Patient-centered Intervention Network (SPIN) is an international collaboration of patient organisations, clinicians and researchers. The aim of SPIN is to develop a research infrastructure to test accessible, low-cost self-guided online interventions to reduce disability and improve HRQL for people living with the rare disease systemic sclerosis (SSc or scleroderma). Once tested, effective interventions will be made accessible through patient organisations partnering with SPIN. Methods and analysis: SPIN will employ the cohort multiple randomised controlled trial (cmRCT) design, in which patients consent to participate in a cohort for ongoing data collection. The aim is to recruit 1500– 2000 patients from centres across the world within a period of 5 years (2013–2018). Eligible participants are persons ≥18 years of age with a diagnosis of SSc. In addition to baseline medical data, participants will complete patient-reported outcome measures every 3 months. Upon enrolment in the cohort, patients will consent to be contacted in the future to participate in intervention research and to allow their data to be used for comparison purposes for interventions tested with other cohort participants. Once nterventions are developed, patients from the cohort will be randomly selected and offered interventions as part of pragmatic RCTs. Outcomes from patients offered interventions will be compared with outcomes from trial-eligible patients who are not offered the interventions. Ethics and dissemination: The use of the cmRCT design, the development of self-guided online interventions and partnerships with patient organisations will allow SPIN to develop, rigourously test and effectively disseminate psychosocial and rehabilitation interventions for people with SSc.(undefined